Takeda Pharmaceutical Co Ltd
TSE:4502
Intrinsic Value
The intrinsic value of one
Takeda Pharmaceutical Co Ltd
stock under the Base Case scenario is
5 572.72
JPY.
Compared to the current market price of 4 171 JPY,
Takeda Pharmaceutical Co Ltd
is
Undervalued by 25%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
Profitability Score
Profitability Due Diligence
Takeda Pharmaceutical Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Takeda Pharmaceutical Co Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Takeda Pharmaceutical Co Ltd's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Takeda Pharmaceutical Co Ltd
Capital Structure
Takeda Pharmaceutical Co Ltd
| Market Capitalization | 6.5T JPY | |
| Total Debt | 4.2T JPY | |
| Minority Interest | 560M JPY | |
| Preferred Equity | 0 JPY | |
| Cash and Equivalents | 798B JPY | |
| Short-Term Investments | 31.9B JPY | |
| Enterprise Value | 9.8T JPY | |
Wall St
Price Targets
Price Targets Summary
Takeda Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Takeda Pharmaceutical Co Ltd
is 4 702.84 JPY
with a low forecast of 3 737 JPY and a high forecast of 7 245 JPY.
Competitive Landscape
Competitors
Takeda Pharmaceutical Co Ltd
Suppliers & Customers
Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd has 107 key suppliers from 13 countries and 17 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Takeda Pharmaceutical Co Ltd has 54 key customers from 9 countries and 7 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Shareholder Return
Price
Takeda Pharmaceutical Co Ltd
| Average Annual Return | -8.46% |
| Standard Deviation of Annual Returns | 22.8% |
| Max Drawdown | -49% |
| Market Capitalization | 6.5T JPY |
| Shares Outstanding | 1 571 786 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Takeda Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,347 full-time employees. The firm is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The firm's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The firm is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one
Takeda Pharmaceutical Co Ltd
stock under the Base Case scenario is
5 572.72
JPY.
Compared to the current market price of 4 171 JPY, Takeda Pharmaceutical Co Ltd is Undervalued by 25%.
